Table 6 Trends of multidrug combinations prescribed for outpatients with migraine between 2018 and 2022
| Â | 2018 | 2019 | 2020 | 2021 | 2022 | Total | P1 | P2 |
|---|---|---|---|---|---|---|---|---|
Outpatients receiving therapeutic drugs* | 1748 | 1916 | 1571 | 1867 | 2104 | 9206 | – | – |
 Monotherapy | 1688 (96.57) | 1828 (95.41) | 1504 (95.74) | 1786 (95.66) | 2043 (97.10) | 8849 (96.12) | 0.462 | 0.250 |
 Combined therapy | 60 (3.43) | 88 (4.59) | 67 (4.26) | 81 (4.34) | 61 (2.90) | 357 (3.88) | 1.000 | 0.250 |
Outpatients receiving preventive drugs | 3337 | 3749 | 3009 | 3839 | 3555 | 17,494 | – | – |
 Monotherapy | 2757 (82.62) | 3069 (81.86) | 2460 (81.75) | 3108 (80.96) | 2841 (79.92) | 14,235 (81.37) | 0.807 | 0.002 |
 Combined therapy | 580 (17.38) | 680 (18.13) | 549 (18.24) | 731 (19.04) | 714 (20.08) | 3259 (18.63) | 0.462 | 0.002 |